Can Oral Levofloxacin and Oral Clindamycin Be Taken Together for Significant Skin Infections?
Yes, oral levofloxacin (Levaquin) and oral clindamycin can be safely taken together for significant skin infections, and this combination is explicitly supported by current guidelines for specific clinical scenarios. 1
Guideline Support for Combination Therapy
The Infectious Diseases Society of America (IDSA) 2014 guidelines specifically recommend ciprofloxacin (a fluoroquinolone like levofloxacin) together with clindamycin as an acceptable combination regimen for moderate to severe diabetic wound infections 1. This establishes clear precedent for fluoroquinolone-clindamycin combinations in serious skin and soft tissue infections.
For neutropenic patients with cancer, the IDSA explicitly lists ciprofloxacin plus clindamycin as an acceptable oral empirical treatment regimen, demonstrating safety and efficacy of this drug class combination 2, 3.
FDA-Approved Indications
Levofloxacin is FDA-approved for both complicated and uncomplicated skin and skin structure infections, including abscesses, cellulitis, furuncles, impetigo, pyoderma, and wound infections 4. The drug label does not list any contraindication or warning against concurrent clindamycin use 4.
Clinical Scenarios Where This Combination Is Appropriate
Moderate to Severe Diabetic Foot Infections
- IDSA guidelines recommend levofloxacin for diabetic wound infections (mild to severe) 1
- Ciprofloxacin plus clindamycin is specifically listed as a combination option for moderate to severe cases 1
- Published clinical data demonstrates successful outcomes with oral clindamycin plus ciprofloxacin in diabetic foot infections, with significant cost savings and reduced hospitalization 5
Coverage Considerations
This combination provides:
- Levofloxacin: Excellent gram-negative coverage (including E. coli, Klebsiella, Proteus), methicillin-susceptible S. aureus (MSSA), and Streptococcus pyogenes 4
- Clindamycin: Enhanced gram-positive coverage (particularly MSSA), anaerobic coverage, and anti-toxin effects against toxin-producing streptococci and staphylococci 1, 6
When MRSA Coverage Is Needed
If methicillin-resistant S. aureus (MRSA) is suspected or confirmed, clindamycin provides appropriate coverage (assuming local susceptibility) 1. Levofloxacin adds broad-spectrum coverage for polymicrobial infections common in significant skin infections 1.
Important Caveats and Monitoring
Potential Antagonism Concern
One in vitro study demonstrated that clindamycin can antagonize the bactericidal activity of fluoroquinolones (levofloxacin and moxifloxacin) against S. aureus 7. However, this finding:
- Was observed only in laboratory conditions, not clinical practice
- Has not translated to clinical failures in published case series 8, 5
- Does not appear in any guideline as a contraindication to combination use 1, 3
Drug Interactions to Monitor
- Warfarin: Levofloxacin can enhance warfarin effects; monitor INR closely if patient is anticoagulated 4
- Antidiabetic agents: Levofloxacin may cause dysglycemia; monitor blood glucose in diabetic patients 4
- NSAIDs: Concurrent use may increase seizure risk 4
Clindamycin Resistance
Check local antibiograms for clindamycin resistance rates in S. aureus 6. In areas with high macrolide resistance (>10%), perform D-test to detect inducible clindamycin resistance 6.
Practical Dosing Approach
For significant skin infections in adults:
- Levofloxacin: 750 mg once daily orally 4
- Clindamycin: 300-450 mg three to four times daily orally 1
- Duration: Typically 7-14 days depending on severity and clinical response 4
When This Combination Is Particularly Useful
- Polymicrobial infections requiring both gram-positive and gram-negative coverage 1
- Diabetic foot infections with moderate severity 1, 5
- Suspected toxin-producing organisms (streptococci or staphylococci) where clindamycin's protein synthesis inhibition provides anti-toxin benefit 6, 9
- Penicillin-allergic patients requiring broad-spectrum coverage 2, 3
Bottom line: This combination is guideline-supported, clinically proven, and safe when appropriately monitored. 1, 3